Please do some research. We've been talking about this on here since May.
We haven't given up on mortality. But as others have replied, also consider the secondary outcomes, including days on mechanical ventilation, apparently the key determinant for Rem-vir approval.
We understand that our trial is taking place in the best teaching and research hospitals in the US. Obviously this will be reflected in the standard of care and mortality for the placebo group.
But we also have confidence in the process and decision making of the DSMB. Particularly in the overall context of the pandemic and its effect on the US.
For example, if you are admitted to an ICU in a smaller US hospital then you have a more than three (3) times higher rate of mortality. The implication for the 50,000+ daily new cases and 1000+ daily deaths geographically right across the US is obvious.
https://www.wbur.org/commonhealth/2020/07/15/covid-hospital-mortality-death-bigger
We believe Mesoblast and Rem-L will a be part of the answer.
GLTAH!
- Forums
- ASX - By Stock
- MSB
- COVID ARDS interim analysis
COVID ARDS interim analysis, page-9
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 75212 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 1.185 |
1 | 20000 | 1.175 |
1 | 5664 | 1.170 |
1 | 17568 | 1.160 |
3 | 56695 | 1.150 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 59712 | 2 |
1.195 | 36255 | 5 |
1.200 | 404381 | 31 |
1.205 | 3000 | 1 |
1.210 | 162475 | 7 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
MSB (ASX) Chart |